Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Kris V. Kowdley, John M. Vierling, Cynthia Levy, Andreas E. Kremer, Ehud Zigmond, Pietro Andreone, Stuart C. Gordon, Christopher L. Bowlus, Eric J. Lawitz, Richard J. Aspinall, Daniel S. Pratt, Karina Raikhelson, Maria S. Gonzalez-Huezo, Michael A. Heneghan, Sook-Hyang Jeong, Alma L. Ladrón de Guevara, Marlyn J. Mayo, George N. Dalekos, Joost P.H. Drenth, Ewa Janczewska, Barbara A. Leggett, Frederik Nevens, Victor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak J. Trivedi, Lisa Forman, David E.J. Jones, Stephen D. Ryder, Mark G. Swain, Alexandra Steinberg, Pol F. Boudes, Yun-Jung Choi, Charles A. McWherter, Unknown

Open source

DOI: 10.1097/hep.0000000000000395
Published: 2023-04-06
Container: Hepatology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/hep.0000000000000395,
  title = {Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study},
  author = {Gideon M. Hirschfield and Mitchell L. Shiffman and Aliya Gulamhusein and Kris V. Kowdley and John M. Vierling and Cynthia Levy and Andreas E. Kremer and Ehud Zigmond and Pietro Andreone and Stuart C. Gordon and Christopher L. Bowlus and Eric J. Lawitz and Richard J. Aspinall and Daniel S. Pratt and Karina Raikhelson and Maria S. Gonzalez-Huezo and Michael A. Heneghan and Sook-Hyang Jeong and Alma L. Ladrón de Guevara and Marlyn J. Mayo and George N. Dalekos and Joost P.H. Drenth and Ewa Janczewska and Barbara A. Leggett and Frederik Nevens and Victor Vargas and Eli Zuckerman and Christophe Corpechot and Eduardo Fassio and Holger Hinrichsen and Pietro Invernizzi and Palak J. Trivedi and Lisa Forman and David E.J. Jones and Stephen D. Ryder and Mark G. Swain and Alexandra Steinberg and Pol F. Boudes and Yun-Jung Choi and Charles A. McWherter and Unknown},
  year = {2023},
  journal = {Hepatology},
  doi = {10.1097/hep.0000000000000395},
  url = {https://doi.org/10.1097/hep.0000000000000395}
}

RIS

TY  - JOUR
TI  - Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study
AU  - Gideon M. Hirschfield
AU  - Mitchell L. Shiffman
AU  - Aliya Gulamhusein
AU  - Kris V. Kowdley
AU  - John M. Vierling
AU  - Cynthia Levy
AU  - Andreas E. Kremer
AU  - Ehud Zigmond
AU  - Pietro Andreone
AU  - Stuart C. Gordon
AU  - Christopher L. Bowlus
AU  - Eric J. Lawitz
AU  - Richard J. Aspinall
AU  - Daniel S. Pratt
AU  - Karina Raikhelson
AU  - Maria S. Gonzalez-Huezo
AU  - Michael A. Heneghan
AU  - Sook-Hyang Jeong
AU  - Alma L. Ladrón de Guevara
AU  - Marlyn J. Mayo
AU  - George N. Dalekos
AU  - Joost P.H. Drenth
AU  - Ewa Janczewska
AU  - Barbara A. Leggett
AU  - Frederik Nevens
AU  - Victor Vargas
AU  - Eli Zuckerman
AU  - Christophe Corpechot
AU  - Eduardo Fassio
AU  - Holger Hinrichsen
AU  - Pietro Invernizzi
AU  - Palak J. Trivedi
AU  - Lisa Forman
AU  - David E.J. Jones
AU  - Stephen D. Ryder
AU  - Mark G. Swain
AU  - Alexandra Steinberg
AU  - Pol F. Boudes
AU  - Yun-Jung Choi
AU  - Charles A. McWherter
AU  - Unknown
PY  - 2023
JO  - Hepatology
DO  - 10.1097/hep.0000000000000395
UR  - https://doi.org/10.1097/hep.0000000000000395
ER  -

APA

Hirschfield, G. M., Shiffman, M. L., Gulamhusein, A., Kowdley, K. V., Vierling, J. M., Levy, C., Kremer, A. E., Zigmond, E., Andreone, P., Gordon, S. C., Bowlus, C. L., Lawitz, E. J., Aspinall, R. J., Pratt, D. S., Raikhelson, K., Gonzalez-Huezo, M. S., Heneghan, M. A., Jeong, S., Guevara, A. L. L. D., Mayo, M. J., Dalekos, G. N., Drenth, J. P., Janczewska, E., Leggett, B. A., Nevens, F., Vargas, V., Zuckerman, E., Corpechot, C., Fassio, E., Hinrichsen, H., Invernizzi, P., Trivedi, P. J., Forman, L., Jones, D. E., Ryder, S. D., Swain, M. G., Steinberg, A., Boudes, P. F., Choi, Y., McWherter, C. A., & Unknown (2023). Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study. Hepatology. https://doi.org/10.1097/hep.0000000000000395

Source records

crossref · retrieved 2026-09-26T08:07:58.214Z